Akums Drugs IPO Description – Founded in 2004, Akums Drugs and Pharmaceuticals has emerged as a prominent player in the pharmaceutical contract development and manufacturing (CDMO) sector, offering an extensive array of pharmaceutical products and services in India and internationally. Distinguished as one of India’s leading CDMOs, Akums holds intellectual property for numerous manufacturing processes for its formulations.
The company has manufactured 4,025 commercialized formulations across over 60 dosage forms. The company manufactured formulations for 26 of the leading 30 pharmaceutical companies in terms of sales in India. The CDMO business, operates 10 manufacturing units, with a cumulative formulations manufacturing capacity of 49.21 billion units annually, as of 30 September 2023.
The company has 60 countries worldwide such as Vietnam, Philippines, Peru, Myanmar, Cambodia, Latvia, Myanmar, Tanzania, and Kenya, among others. As of 30 September 2023, key clients for the CDMO business include Alembic Pharmaceuticals, Alkem Laboratories, Cipla, Dabur India, Dr. Reddy’s Laboratories, Mankind Pharma, MedPlus Health Services, Natco Pharma, Sun Pharmaceutical Industries, and Amishi Consumer Technologies (The Mom’s Co), among others.
Promoters of Akums Drugs – Sanjeev Jain, Sandeep Jain, and Akums Master Trust
Akums Drugs IPO Details
| Akums Drugs IPO Dates | Coming soon |
| Akums Drugs Issue Price | Coming soon |
| Fresh issue | INR 680 crore |
| Offer For Sale | 1,85,98,365 shares |
| Total IPO size | Coming soon |
| Minimum bid (lot size) | Coming soon |
| Face Value | INR 2 per share |
| Retail Allocation | 10% |
| Listing On | NSE, BSE |
Akums Drugs Financial Performance
| Â | FY 2021 | FY 2022 | FY 2023 | H1 FY 2024 |
| Revenue | 2,722.63 | 3,671.89 | 3,654.82 | 2,151.14 |
| Expenses | 2,561.87 | 3,874.95 | 3,475.93 | 2,210.51 |
| Net income | 123.44 | (250.87) | 97.82 | (154.74) |
| Margin (%) | 4.53 | (6.83) | 2.68 | 7.19 |
Akums Drugs Offer News
Akums Drugs Valuations & Margins
| FY 2021 | FY 2022 | FY 2023 | FY 2024 (Post-Issue)* | |
| EPS | 8.58 | (17.65) | 6.63 | (10.93) |
| PE Ratio | – | – | – | – |
| FY 2021 | FY 2022 | FY 2023 | |
| RONW (%) | 13.87 | (40.60) | 13.23 |
| NAV | 61.85 | 43.48 | 50.13 |
| ROCE (%) | 21.06 | (18.89) | 24.60 |
| EBITDA (%) | 9.42 | (1.87) | 10.38 |
| Debt/Equity | 0.11 | 0.58 | 0.75 |
Akums Drugs IPO GMP Today (Daily Trend)
Akums Drugs IPO Objectives
The company proposes to utilize the Net Proceeds from the Fresh Issue towards funding the following objects:
- Repayment/ prepayment of indebtedness of the company and its subsidiaries – INR 387 crore
- Funding incremental working capital requirements of the company – INR 55 crore
- Pursuing inorganic growth initiatives through acquisitions
- General corporate purposes
Akums Drugs IPO Subscription – Live Updates
Coming soon
Akums Drugs – Comparison With Listed Peers
| Company | PE ratio | EPS | RONW (%) | NAV | Revenue (Cr.) |
| Akums Drugs and Pharmaceuticals | – | 6.63 | 13.23 | 50.13 | 3,654.82 |
| Divi’s Laboratories | 53.86 | 68.69 | 14.28 | 480.93 | 7,765.51 |
| Suven Pharma | 40.41 | 16.16 | 23.70 | 68.16 | 1,340.33 |
| Gland Pharma | 42.55 | 47.43 | 9.81 | 483.41 | 3,624.60 |
| Torrent Pharma | 71.86 | 36.79 | 20.09 | 183.13 | 9,620.15 |
Akums Drugs IPO Allotment Status
Akums Drugs IPO allotment status will be available on Link Intime’s website. Click on Link Intime IPO weblink to get allotment status.
Akums Drugs IPO Dates & Listing Performance
| IPO Opening Date | Coming soon |
| IPO Closing Date | Coming soon |
| Finalization of Basis of Allotment | Coming soon |
| Initiation of refunds | Coming soon |
| Transfer of shares to demat accounts | Coming soon |
| Akums Drugs IPO Listing Date | Coming soon |
| Opening Price on NSE | Coming soon |
| Closing Price on NSE | Coming soon |
Akums Drugs IPO Reviews – Subscribe or Avoid?
Angel One –
Anand Rathi –
Antique Stock Broking –
Arihant Capital –
Ashika Research –
BP Wealth –
Capital Market –
Canara Bank Securities –
Choice Broking –
Dalal & Broacha –
Elite Wealth –
GCL Broking –
Geojit –
GEPL Capital –
Hem Securities –
ICICIdirect –
Indsec –
Jainam Broking –
DR Choksey –
LKP Research –
Marwadi Financial –
Systematix Shares –
Mehta Equities –
Nirmal Bang –
Reliance Securities –
Sushil Finance –
Samco Securities –
SBI Securities –
SMC Global –
SMIFS –
Swastika Investmart –
Ventura Securities –
Akums Drugs Offer Lead Manager
ICICI SECURITIES LIMITED
ICICI Venture House Appasaheb Marathe Marg Prabhadevi
Mumbai 400 025 Maharashtra, India
Phone: +91 22 6807 7100
Email: [email protected]
Website: www.icicisecurities.com
Akums Drugs Offer Registrar
LINK INTIME INDIA PRIVATE LIMITED
C-101, 1st Floor, 247 Park Lal Bahadur Shastri Marg,
Vikhroli (West) Mumbai 400 083, Maharashtra, India
Tel:Â (+91) 81081 14949
E-mail: [email protected]
Website:Â www.linkintime.co.in
AKUMS DRUGS AND PHARMACEUTICALS LIMITED
Plot no. 131 to 133, Block C, Mangolpuri, Ind. Area,
Phase 1, Delhi – 110 083, India
Phone:Â +91 11 6904 1000
Email: [email protected]
Website: www.akums.in
Akums Drugs IPO FAQs
How many shares in Akums Drugs IPO are reserved for HNIs and retail investors?
The investors’ portion for QIB – 75%, NII – 15%, and Retail – 10%.
How to apply for an Akums Drugs Public Offer?
The best way to apply for Akums Drugs public offer is through Internet banking ASBA (know all about ASBA here). You can also apply online through your stock broker using UPI. If you prefer to make paper applications, fill up an offline IPO form and deposit the same to your broker.
What is Akums IPO GMP today?
Akums Drugs IPO GMP today is INR per share.
What is Akums Drugs kostak rate today?
Akums Drugs kostak rate today is INR NA per application.
What is Akums Drugs Subject to Sauda rate today?
Akums Drugs Subject to Sauda rate today is INR per application.
